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Abstract
Background: Substitution with opioid-agonists (e.g., methadone) has shown to be an effective treatment for
chronic long-term opioid dependency. Patient satisfaction with treatment has been associated with improved
addiction treatment outcomes. However, there is a paucity of studies evaluating patients’ satisfaction with Opioid
Substitution Treatment (OST). In the present study, participants’ satisfaction with OST was evaluated at 3 and 12
months. We sought to test the relationship between satisfaction and patients’ characteristics, the treatment
modality received and treatment outcomes.
Methods: Data from a randomized controlled trial, the North American Opiate Medication Initiative (NAOMI),
conducted in Vancouver and Montreal (Canada) between 2005-2008, was analyzed. The NAOMI study compared
the effectiveness of oral methadone vs. injectable diacetylmorphine over 12 months. A small sub-group of patients
received injectable hydromorphone on a double blind basis with diacetylmorphine. The Client Satisfaction
Questionnaire (CSQ-8) was used to measure satisfaction with treatment. CSQ-8 scores, as well as retention and
response to treatment, did not differ between those receiving hydromorphone and diacetylmorphine at 3 or 12
months assessments; therefore, these two groups were analyzed together as the ‘injectable’ treatment group.
Results: A total of 232 (92%) and 237 (94%) participants completed the CSQ-8 at 3 and 12 months, respectively.
Participants in both groups were highly satisfied with treatment. Independent of treatment group, participants
satisfied with treatment at 3 months were more likely to be retained at 12 months. Multivariate analysis indicated
that satisfaction was greater among those randomized to the injection group after controlling for treatment
effectiveness. Participants who were retained, responded to treatment, and had fewer psychological symptoms
were more satisfied with treatment. Finally, open-ended comments were made by 149 (60.3%) participants;
concerns about the randomization process and the study ending were most commonly reported by participants
receiving the oral and injectable medications, respectively.
Conclusions: The higher satisfaction among those receiving medically prescribed injectable diacetylmorphine (or
hydromorphone) supports current evidence regarding the attractiveness of this treatment for long-term, opioid-
dependent individuals not benefiting sufficiently from other treatments. In addition, the measurement of treatment
satisfaction provides valuable information about participants at risk of relapse and in need of additional services.
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Opioid dependence is a chronic relapsing disease that
when untreated can lead to moderate to severe health
consequences such as blood-borne viral infections,
endocarditis, and drug overdoses [1,2]. Treatment for
opioid dependence can be focused on achieving absti-
nence of any drugs or aimed at reducing the adverse
health consequences associated with opioid dependence.
Also, delivery of opioid dependence treatment can be
short or long-term and at in or out-patient settings. Psy-
chotherapy and counselling can be provided alone or in
combination with other treatments [3-5].
Substitution with opioid-agonists (e.g., methadone) is a
long-term treatment aimed at reducing the use of illicit
opioids and its associated problems, including reduced
illicit drug use and illegal activities, human immunodefi-
ciency virus (HIV) infections, as well as improved gen-
eral health and psychosocial adjustment [2,3,6]. In
addition, patients on Opioid Substitution Treatment
(OST) are effectively retained [7], and studies have
shown that the time patients remain in treatment is
associated with greater improvements in the above men-
tioned areas [8]. The delivery of OST varies widely, even
in the same region, in its setting, philosophy, availability
of ancillary services, and policies. Several manuals and
guidelines for best practices have been developed for
health care providers as well as for specific professional
roles [9,10].
It is common for health care services to routinely
assess patient’s satisfaction with received treatments in
order to gain feedback which can be used to improve
the services provided. Satisfaction with received care can
be used as a measure of quality of care and perceived
benefits of a service [11,12]; however, this is a multi-
dimensional concept and it is affected by a wide range
of factors. For instance, satisfaction may be influenced
by the characteristics of the patient (e.g., expectations,
demographic characteristics, beliefs, previous treatment
experiences, etc.), the illness being treated (e.g., acute vs.
chronic), the treatment modalities being used (e.g., inpa-
tient vs. outpatient), and the characteristics of the indivi-
dual providing the treatment (e.g., authoritarian,
tolerant, etc.) [11-16].
Client satisfaction has been evaluated in addiction
treatment services, including OST, though, to a much
lesser degree than other areas of care [17-20]. Although
patients tend to report high levels of satisfaction with
addiction treatment [12,13,15,21,22], patients receiving
OST have also expressed concerns related to the
demands of this treatment. For example, concerns
regarding the procedures of clinics, including dispensing
schedules [20], prolonged waiting times and lack of
access to ancillary services [23] have been perceived as
having an impact on patients’ satisfaction with OST.
Moreover, Perez de los Cobos et al., [18] reported that
the number of hours per week that methadone was dis-
pensed was independently associated with treatment
satisfaction, and a later study found that patients’ who
had a high regard of methadone as a medication for
treating opioid dependence were more satisfied [19].
Client satisfaction has also been linked with a number
of favourable addiction treatment outcomes, including
higher service use [15,24], r e d u c t i o ni ns u b s t a n c eu s e
[15,24-27], greater physical and mental health [25], psy-
chosocial improvements [26], and greater retention in
treatment [12,16,26]. For example, Kelly et al. [26]
recently determined a negative association between
patients’ treatment satisfaction and illicit drug use and
illegal activity at 3 months after OST initiation and a
positive association with treatment retention at 12
months. In contrast, in an outpatient alcohol and drug
treatment setting that provided intensive treatment by
patient education, group therapy, and social support,
McLellan & Hunkeler [28] did not find an association
between patient satisfaction and treatment outcomes at
6 months follow-up.
Between 2005 and 2008 a randomized controlled trial
(RCT) comparing the effectiveness of two OST modal-
ities for the treatment of long-term, treatment-resistant
opioid dependence, was carried out in Vancouver and
Montreal (Canada). This study analyses data from that
trial with the purpose to: a) determine participants’
satisfaction with the treatment received; and b) test if
satisfaction scores vary according to patients’ character-
istics, the treatment modality received and treatment
outcomes.
Methods
Design, Setting and Participants
The North American Opiate Medication Initiative
(NAOMI) was an open-label, phase III RCT comparing
supervised injectable diacetylmorphine and oral metha-
done in the treatment of long-term opioid dependence.
For the purpose of validating self-reported use of street
heroin by urine testing, a small group of participants
were randomized to receive injectable hydromorphone
in double-blind basis instead of diacetylmorphine. Parti-
cipants were aged 25 or greater, with at least 5 years of
opioid dependence (according to DSM-IV criteria), cur-
rent daily injection of opioids, a minimum of two pre-
vious treatments for opioid dependence, including at
least one OST attempt and no enrolment in OST
within the prior 6 months. Data regarding participants
demographics, substance use before and during the
study, dosage and monitoring issues have been pub-
lished elsewhere [29-31]. Briefly, at treatment entry,
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with heroin and cocaine being the two most frequent
drugs reported in lifetime and prior month. Compari-
sons between Vancouver and Montreal showed that a
higher proportion of Vancouver participants were
Aboriginal (31.6% vs. 0.0%), had unstable housing
(88.5% vs. 22.0%) and had more days of smoked crack
cocaine use (16.88 vs. 2.25) in relation to Montreal [31].
During treatment, illicit heroin use declined drastically
among those randomized to injectable diacetylmorphine
(from 26.6 to 5.3 days), while days of cocaine use
remained stable, as per intention-to-treat (ITT) analysis
[29]. After excluding each participant’s initial 90 day
dose adjustment, the average dose during the study per-
iod for participants receiving diacetylmorphine, hydro-
morphone, or methadone was 395.8 mg, 186.7 mg and
96.0 mg, respectively [32]. High-performance liquid
chromatography testing was used to detect the presence
of morphine and 6-monoacetylmorphine, as evidence of
illicit heroin use in urine samples of the methadone and
hydromorphone groups, which showed a significantly
higher use of illicit heroin in the methadone compared
to hydromorphone group [33].
A total of 251 individuals were randomized to receive
either oral methadone (n = 111), injectable diacetylmor-
phine (n = 115) or injectable hydromorphone (n = 25),
t h el a t t e rt w oo nad o u b l eb l i n db a s i s .P a r t i c i p a n t s
administered the injection medications up to three
times daily (up to 1,000 mg per day) under the supervi-
sion of clinic staff; oral methadone was dispensed daily.
Participants were offered psychosocial and primary
care; in keeping with Health Canada Best Practices, all
services were delivered in a patient-centred fashion [9].
Participants received their allocated treatment for 12
months. Since the injectable medications are not
licensed in Canada for the treatment of opioid-depen-
dency, an additional 3-month period was provided to
taper and transition those participants to other treat-
ment modalities (primarily methadone). The University
of British Columbia/Providence Health Care research
ethics board approved the study, and all participants
provided written informed consent.
Measures
A separate research team obtained outcome evaluations
at baseline and follow-up (3, 6, 9 and 12 months), using
the European Addiction Severity Index (EuropASI; [34])
and Maudsley Addiction Profile (MAP; [35]). Partici-
pants were considered retained to addiction treatment if
they received study medication on at least 10 out of the
14 days prior to the follow-up assessment or were con-
firmed to be in any other treatment program or absti-
nent of opioids during this interval. Participants were
regarded as treatment compliant if they received the
treatment they were allocated to for at least 20 out of
the prior 30 days (i.e., those that were randomized to
injectable medication continued to receive injectable;
those randomized to optimised methadone were still
receiving methadone at the study clinic). Overall clinical
response was defined as an improvement of at least 20%
in Drug and/or Legal EuropASI composite scores, with
no deterioration higher than 10% in more than one of
the remaining composite scores. All participants lost to
follow-up were considered non-retained.
Participants’ satisfaction with treatment was evaluated
at 3 and 12 months using the Client Satisfaction Ques-
tionnaire (CSQ; [36], 8-item version [37]. The CSQ-8
assesses global patient satisfaction with a 4-point Likert
type scale and also provides a general score ranging
from 8 to 32. This questionnaire has been used in psy-
chiatric inpatient and outpatient treatment evaluations
[38,39] as well as in substance abuse treatment settings
[40], including OST [21,22,41-44]. The CSQ-8 includes
the following questions: 1) How would you rate the
quality of service received?; 2) Did you get the kind of
service you wanted?; 3) To what extent has our pro-
gramme met your needs?; 4) If a friend were in need of
similar help, would you recommend our programme to
him or her?; 5) How satisfied are you with the amount
of help you have received?; 6) Have the services you
received helped you to deal more effectively with your
problems?; 7) In an overall, general sense, how satisfied
are you with the service you have received?; 8) If you
were to seek help again, would you come back to our
programme? At the end of the questionnaire partici-
pants had the option to make comments or suggestions.
Analysis
Item and total mean treatment satisfaction scores were
calculated for each participant and to obtain a global
satisfaction score. The groups receiving hydromorphone
and diacetylmorphine did not differ at 3 or 12 months
assessments in their CSQ-8 scores; therefore, these two
groups were analyzed together as the ‘injectable’ treat-
ment group. Comparisons of client satisfaction between
treatment groups (injectable diacetylmorphine or hydro-
morphone vs. oral methadone) were carried out using
Student’s t and Mann-Whitney U depending on variable
distribution, as well as for retention in addiction treat-
ment and clinical response.
Similar to other studies [12,13,15], participants scored
very high on treatment satisfaction, and as a conse-
quence the variable’s distribution was skewed. To fit
into the multivariate models, mean satisfaction scores
were organized according to 3 levels of satisfaction: 1)
dissatisfied or least satisfied (8-16); 2) satisfied (17-30);
and 3) very satisfied (31-32). Satisfaction scores were
evaluated in relation to patient characteristics (age,
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3 and 12 months follow-up (EuropASI; MAP). A multi-
variate logistic regression analysis, adjusted by treatment
group, was used to determine if total and each item of
the client satisfaction questionnaire at 3 months pre-
dicted treatment outcomes at 12 months. Finally, a mul-
tivariate proportional odds model estimated by
Generalized Estimating Equation (GEE) algorithm was
performed to determine predictors of treatment satisfac-
tion for total score and each individual question. Rando-
mization group, gender, ethnicity, age, and site were
included in the model whether significant or not. All
other variables remained in the model only if significant.
Missing values were considered as missing. Analyses
were performed by an ITT basis. Data was analyzed
using SAS
® (version 9.1.3).
The open-ended qualitative responses provided in the
CSQ-8 ‘comments and suggestions’ section were also
analysed. To start, two researchers read all comments
(EOJ; KM) and an initial list of themes were developed.
The researchers then independently coded each com-
ment according to these themes. Finally, the researchers
decided on a list of 12 common categories based on the
frequency which participants mentioned them: positive
or negative comments about the staff and the program,
desire that study eligibility criteria were easier, frustra-
tion with the randomization process, dissatisfaction with
medication dose received, lack of attention to their pain
management, extension of clinic operation hours,
request for more ancillary services, request of nutritional
services, concerns regarding the interactions in the clinic
while waiting for the medication, lengthy pre-post injec-
tion assessment, insufficient time allotted to inject, and
disappointments of the study ending. A univariate logis-
tic GEE model was applied to find subgroups of
participants most likely to make open-ended comments
at 3 and 12 months follow-up.
Results
A total of 88 (91%) women and 144 (93%) men com-
pleted the CSQ-8 at 3 months; at 12 months, 91 (94%)
women and 146 (95%) men completed the CSQ-8. Com-
pared to participants in the oral methadone group, those
randomized to the injection group had a significantly
higher total satisfaction score at both 3 and 12 months
(Table 1). These participants also showed significantly
higher satisfaction scores for CSQ item 3 (program
meeting their needs), item 6 (the services helped them
to deal with their problems) a n di t e m8( w i l l i n g n e s st o
return for treatment in the future).
After adjusting for treatment group, the CSQ item 3
(to what extent has our programme met your needs) at
3 months significantly predicted retention outcomes at
12 months. Compared to participants who answered
that none or few of their needs had been met, those
most satisfied and satisfied at 3 months, were more
likely to be retained to addiction treatment at 12
months (most satisfied Odds Ratio [OR] = 6.2; 95%
Confidence Interval [CI] = 2.23, 17.39; p = 0.001; satis-
fied OR = 3.3; 95% CI = 1.5-7.1; p = 0.003). Similar
results were obtained for retention to allocated treat-
ment; however, 3 month satisfaction did not predict 12
month treatment response.
Table 2 displays the multivariate GEE analysis for total
satisfaction and each item score of the CSQ-8. Rando-
mization to the injectable group, younger age, better
psychological health, and less drug use predicted treat-
ment satisfaction in most of the scores. Compared to
women, and non-Aboriginal participants, men and
Aboriginal participants tend to be less satisfied.
Table 1 Treatment Satisfaction by treatment group and time
T3 T12
Treatment Satisfaction Questions
a Oral Injection Oral Injection
MS DMS DMS DMS D
Quality of service received 3.2 0.95 3.4 0.76 3.3 0.85 3.3 0.86
Get the kind of service wanted
b 2.7 1.15 3.5 0.64 3.0 1.11 3.2 0.86
The program met the needs
b; c 2.4 1.03 3.2 0.70 2.7 1.02 3.2 0.83
Would recommend the program
b 3.3 0.96 3.8 0.45 3.3 0.93 3.6 0.84
Satisfied with the amount of help received
b 2.9 0.97 3.4 0.67 3.1 0.95 3.2 0.89
The services helped to deal with problems
b; c 2.8 0.95 3.6 0.63 3.0 0.88 3.3 0.80
General satisfaction with the service received
b 2.9 1.02 3.4 0.70 3.1 0.91 3.2 0.92
Would come back
b; c 3.2 0.92 3.7 0.53 3.4 0.86 3.6 0.68
Total Satisfaction
b; c 23.6 6.41 28.0 3.78 24.8 6.00 26.5 5.28
a Refers to questions and total score from CSQ-8
b Differences between groups significant (p < 0.01) at 3 months
c Differences between groups significant (p < 0.04) at 12 months.
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Page 4 of 10Table 2 Multivariate Generalized Estimating Equation model for predictors of treatment satisfaction
Variable TotalS
i † Q1
i † Q2
i † Q3
i † Q4
i † Q5
i † Q6
i † Q7
i † Q8
i †
Randomization group:
Injectable vs. Oral
1.32
(0.81-2.16)
1.05
(0.74-1.50)
1.81
(1.26-2.59)
2.40
(1.61-3.56)
1.94
(1.26-2.98)
1.14
(0.78-1.67)
2.35
(1.62-3.41)
1.16
(0.79-1.72)
2.29
(1.51-3.48)
Gender:
Male vs. Female
0.65
(0.41-1.03)
0.84
(0.58-1.21)
0.75
(0.52-1.07)
0.82
(0.56-1.20)
0.55
(0.36-0.86)
0.74
(0.51-1.09)
0.74
(0.51-1.08)
0.86
(0.60-1.25)
0.63
(0.42-0.96)
Age 0.71
(0.54-0.95)
0.99
(0.80-1.22)
0.81
(0.65-1.00)
0.69
(0.55-0.86)
0.68
(0.52-0.88)
0.74
(0.58-0.93)
0.79
(0.63-1.00)
0.75
(0.60-0.94)
0.78
(0.60-1.00)
Ethnicity:
Aboriginal vs. Non-Aboriginal
0.70
(0.41-1.20)
0.80
(0.53-1.22)
0.76
(0.50-1.15)
0.99
(0.65-1.49)
0.55
(0.34-0.89)
1.01
(0.67-1.54)
0.99
(0.63-1.55)
0.72
(0.47-1.11)
0.50
(0.31-0.81)
Site:
Vancouver vs. Montreal
0.97
(0.54-1.74)
0.72
(0.45-1.16)
1.51
(0.98-2.33)
1.31
(0.82-2.10)
2.16
(1.31-3.54)
1.19
(0.75-1.88)
1.07
(0.68-1.69)
1.00
(0.63-1.58)
1.74
(1.06-2.84)
Treatment Compliance:
a
Yes vs.N o
1.80
(1.08-3.01)
- 2.18
(1.51-3.12)
- 2.44
(1.60-3.72)
1.97
(1.37-2.86)
2.10
(1.45-3.03)
- 1.95
(1.29-2.94)
Treatment Response:
b
Yes vs.N o
-- 1.53
(1.09-2.13)
-- 1.52
(1.06-2.17)
--
Treatment Retention:
c
Yes vs.N o
--- 2.31
(1.41-3.80)
-- - 2.15
(1.36-3.40)
Current Psychological Symptoms
d 0.94
(0.91-0.97)
- 0.95
(0.93-0.97)
0.95
(0.93-0.97)
0.95
(0.93-0.97)
0.96
(0.94-0.98)
0.95 (0.93-0.97) 0.95 (0.93-0.97) 0.95 (0.92-0.97)
Current Physical Health
d - 0.95
(0.93-0.97)
---- - - -
Current Legal Situation
e --- 0.92
(0.85-0.99)
- - ---
Current Drug Use
e 0.81
(0.72-0.92)
0.96
(0.93-0.99)
- 0.79
(0.71-0.87)
0.89
(0.80-0.99)
0.90
(0.82-1.00)
0.85
(0.78-0.94)
0.81
(0.74-0.89)
-
Family/Social Relations
e ------ -- 0.90
(0.82-0.99)
Heroin Use at Baseline
f ----- 0.96
(0.94-0.99)
---
† Refers to CSQ-8 (TotalS: Total Satisfaction score; Q1: How would you rate the quality of service received; Q2: Did you get the kind of service you wanted; Q3: To what extent has our program met your needs; Q4: If
a friend were in need of similar help, would you recommend our program to him or her; Q5: How satisfied are you with the amount of help you have received; Q6: Have the services you received helped you to deal
more effectively with your problems; Q7: In an overall, general sense, how satisfied are you with the service you have received; Q8: If you were to seek help again, would you come back to our program?)
i Odds Ratio (95% Confidence Interval). P values highlighted: p ≤ 0.05
(a) Retention to allocated treatment: at least 20 out of prior 30 days;
(b) Treatment response defined as improvement of at least 20% in Drug and/or Legal EuropASI composite scores, with no deterioration higher than 10% in more than one of the remaining composite scores;
(c) Retention to addiction treatment or abstinent: at least 10 out of prior 14 days;
(d) MAP (Maudsley Addiction Profile) in the prior month. Scores range from 0 to 40; higher scores are indicative of more severe problems. Higher scores are indicative of more severe problems;
(e) EuropASI (European version of the Addiction Severity Index) in the prior month. Sub-scale scores range from 0 to 1; higher scores are indicative of more severe problems;
(f) In the prior 30 days.
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0Participants who were compliant, retained and
responded to treatment also tended to be more satisfied.
Open-ended comments about treatment satisfaction
and perceptions were provided by 149 (60.3%) of the
participants. Participants who were older (OR = 1.5;
95% CI = 1.2- 1.9; p = 0.002), interviewed in Vancouver
(OR = 6.8; 95% CI = 3.9- 12.0; p = < 0.0001), and who
were receiving their allocated treatment in the prior
month (OR = 6.8; 95% CI = 3.9-12.0; p = 0.0251) were
significantly more likely to make open-ended comments.
Table 3 shows that general comments about staff and
the program were made by 43 (38.7%) and 54 (58.7%)
participants at 3 months and at 12 months, respectively.
Concerns about randomization were mostly mentioned
at 3 months compared to the 12 month evaluation,
while disappointments about the end of study were
mentioned more frequently at 12 months. When com-
paring comments made by oral (n = 86) and injectable
(n = 120) treatment groups, individuals in the latter
group made more general comments about the staff and
program and these also tended to be more positive.
Only participants receiving the oral medication
expressed their frustration with the randomization pro-
cess, while disappointments about the study ending
were mentioned more by those in the injection group.
Discussion
The present study determined participants’ satisfaction
with received treatments in the first North American
RCT to provide injectable diacetylmorphine or hydro-
morphone compared to oral methadone for the treat-
ment of long-term, treatment resistant, opioid-
dependency. At 3 and 12 months, participants were
satisfied with the treatment received during the study
period, although satisfaction was greater for those ran-
domized to receive injectable treatments. At 3 months,
participants who reported that the program met their
needs were more likely to be retained at 12 months. To
our knowledge this is the first study to assess treatment
satisfaction among participants receiving supervised
injectable diacetylmorphine or hydromorphone.
Regardless of the outcome of the randomization, parti-
cipants in the trial were highly satisfied with the treat-
ment received. This follows previous studies which have
c o n s i s t e n t l yf o u n dt h a tp a t i e n t st e n dt or e p o r th i g h
levels of treatment satisfaction, including community
health services [45], services for mental health [13],
addiction [46], and opioid dependence [20]. In a meta-
analytic review of patient satisfaction with mental health
services, it was suggested that the high skewness
towards positive satisfaction scores might be due to the
lack of clarity of norms against which to compare the
treatments, the psychometric properties of the instru-
ments used, and the lack of a specific theoretical frame-
work of patient satisfaction [13]. The factor structure
(uni-dimensional vs. multi-dimensional) of an instru-
ment can also have an impact on the sensitivity and
validity of the instrument’s ability to measure satisfac-
tion [47]; therefore, uni-dimensional instruments might
overestimate participants’ satisfaction because partici-
pants are dichotomously categorized as being either
satisfied or dissatisfied. More recently, in a European
review of outpatient care, Saila et al. [12] suggested that
the generally high levels of satisfaction may also reflect
Table 3 Categories of comments by group
Comments
a Oral
n=8 6
Injection
n = 120
Total
n = 206
n (%) n (%) n (%)
Comments about staff and program 28 32.6 69 57.5 97 47.1
Positive 24 27.9 54 45.0 78 80.4
Negative 4 4.7 15 12.5 19 19.6
Easier eligibility 5 5.8 4 3.3 9 4.4
Dissatisfaction with Dosage 1 1.2 7 5.8 8 3.9
Frustration with Randomization 31 36.0 0 0.0 31 15.0
Insufficient Pain Management 3 3.5 1 0.8 4 1.9
Extension of Clinic Operation Hours 8 9.3 4 3.3 12 5.8
Request More Ancillary services 3 3.5 5 4.2 8 3.9
Request More Nutritional services 3 3.5 5 4.2 8 3.9
Concerns of Interactions in the Waiting Room 0 0.0 8 6.7 8 3.9
Lengthy Pre-Post Injection Assessment 0 0.0 8 6.7 8 3.9
Insufficient Time Allotted to Inject 0 0.0 4 3.3 4 1.9
Disappointments of the Study Ending 3 3.5 20 16.7 23 11.2
a All comments were derived from the open-ended remarks section of the CSQ-8. Comments were not mandatory.
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publish findings that are favourable to their particular
programs or services. Another hypothesis to consider is
that an ill person who receives care will most likely be
grateful to the caregiver, adding to the positive skewness
in satisfaction scores found in the literature as well as in
this study.
In spite of being highly satisfied, participants who
reported that the program met their needs at three-
months were more likely to be retained in treatment at
12 months. Several other studies have reported a similar
association between satisfaction and retention to addic-
tion treatment services [12,26,41,46]. In particular, Kelly
et al. [26] recently found that those participants who
were retained in OST at 12 months were more satisfied
with the program at 3 months. Therefore, the integra-
tion of client satisfaction surveys early in the treatment
program may be a useful tool to identify participants
who are at risk for treatment dropout and relapse.
In the present study, participants randomized to
receive injectable medications were significantly more
satisfied than those randomized to oral methadone even
after controlling for age, gender, ethnicity, treatment
retention, treatment compliance and treatment response.
Furthermore, differences in satisfaction scores between
treatment groups were not the result of patient charac-
teristics at baseline (e.g., age, gender, education, drug
use severity, health). To date, there is very limited data
on treatment satisfaction among opioid-dependent indi-
viduals receiving injectable OST. In the only study (to
our knowledge) that assessed client satisfaction among
patients receiving (in the UK) injectable OST (diacetyl-
morphine or methadone), those receiving diacetylmor-
phine were more satisfied, indicating the treatment was
more beneficial because of the ease of injecting diacetyl-
morphine as well as their preference for this drug over
methadone [20]. The higher client satisfaction scores
among participants receiving injectable diacetylmorphine
(or hydromorphone) indicate that this is a treatment
that long-term opioid-dependent individuals would like
to receive. This is highly relevant when considering that
these individuals are often difficult to engage and retain
in treatment, and when untreated are at greater risk for
mortality and morbidity [1,2,48].
In our multivariate analysis, older age was strongly
associated with treatment satisfaction. In addition, men
and Aboriginal participants were less likely to recom-
mend the program to friends or relatives (CSQ-Q4) and
to respond that they would return in the future for a
similar program (CSQ-Q8). Studies in psychiatric and
prison based settings have found older participants to be
more satisfied with treatment [49,50], and it was sug-
gested that older patients may be more adaptable,
respectful, and have lower expectations as a result of
having more previous treatment experiences. In con-
trast, younger patients have fewer previous experiences
with which to compare their treatment, and may be
more defiant toward other patients and staff. The asso-
ciation between gender and treatment satisfaction is less
consistent; however, in one review of treatment satisfac-
tion with general health care services, it was suggested
that women and older patients tend to be more satisfied
with treatment [51]. Regarding ethnicity, there is a pau-
city of data reporting an association between treatment
satisfaction and participants’ ethnicity. In their review,
Aharony et al. [51] briefly mention one study that found
lower satisfaction among African American participants
compared to Caucasian participants. Therefore, given
the state of the current literature it is difficult to inter-
pret our findings regarding the association between
socio-demographic factors and treatment satisfaction.
To our knowledge this is the first study that has consid-
ered Aboriginal ethnicity in the evaluation of treatment
satisfaction with OST in Canada. Previous analyses of
this study data have demonstrated no differences in
treatment effectiveness by ethnicity [52]. However, in
our multivariate model that controls for treatment effec-
tiveness, Aboriginal participants were less satisfied with
the treatment program. These findings are highly rele-
vant when considering that there is data indicating that
Aboriginal people are less likely to access methadone
maintenance treatment [52,53] and face specific barriers
[54]. Treatment satisfaction might be a useful tool to
identify treatment needs among Aboriginal people with
chronic long-term opioid dependence.
Treatment compliance, response, retention and drug
use have previously been associated with treatment
satisfaction [12]. For example, studies have found an
association between client satisfaction and a reduction
in substance use during [26] and after the treatment
period [25,27,55,56]. Therefore, the results obtained in
our study, where lower drug use, higher retention,
response and compliance with treatment were positively
associated with treatment satisfaction, were expected.
Satisfaction with treatment in the present study was
also more likely among those with better psychological
status. In a recent study, Hser et al. [46] found that par-
ticipants with severe psychological and physical health
symptoms at treatment initiation were more satisfied
when provided with additional intense services. More-
over, Kelly et al. [26] found that patients with the great-
est treatment needs had more psychological problems.
Together, these results suggest that unmet treatment
needs may be greater among participants with worse
psychological health, which may contribute to lower
satisfaction with the services provided. Thus, satisfaction
with treatment may be an indicator of participants’
treatment needs.
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the oral group expressed their concern with the rando-
mization process, while those in the injection group
were more worried about the study ending. It is well
known that in clinical trials, randomization to the less
desired treatment condition (e.g., placebo, treatment as
usual) might have a significant impact on participants
willingness to adhere and comply with the study proto-
col; this is especially true in drug and alcohol treatment
settings where attendance is already low [57]. Reviews of
recruitment in RCTs have established that one of the
most common concerns participants express is their
uncertainty with the study medications and not being
randomized to their preferred treatment [58,59]. As a
result, participants are often dissatisfied with their treat-
ment allocation [59]. Although participants in this study
understood the probability of being randomized to the
oral group, the desired treatment condition was inject-
able diacetylmorphine. Thus, it is critical to consider
and assess how the randomization process impacts par-
ticipants, and highlight the need of the provision of
additional supports for participants and recruitment
staff in this phase of a study.
In addition to common concerns among participants
in RCTs, comments regarding the provision of OST
were also expressed in the present study. Clinic operat-
ing hours, as an aspect of the treatment delivery that
could be improved, were mentioned in participants’
comments, and mostly by those in the oral treatment
group. This result is consistent with a previous study of
treatment satisfaction among patients receiving MMT,
where the number of hours per week that methadone
was dispensed was the only variable that predicted client
satisfaction [18]. Comments that were specific to those
in the injectable group included interactions in the wait-
ing room, the lengthy time required for pre- and post-
injection assessments as well as insufficient time per-
mitted in the injection room. It is well known that the
demands of injectable OST are much greater for both
patients and staff; patients receiving injectable treatment
in the NAOMI study attended the clinic up to 3 times
daily, for approximately 1 hour each visit. Considering
the benefits associated with injectable treatments and
the overall greater satisfaction among patients receiving
this form of treatment, these issues are being further
explored with both patients and staff for future studies.
Limitations derived from the design of the parent
study have been discussed elsewhere [29]. It is impor-
tant to note that the NAOMI sample is a very homoge-
nous group of opioid-dependent individuals with several
previous drug treatment attempts that have been inject-
ing drugs for an average of 15 years and were not bene-
fiting from the available addiction treatment system.
Also, for our theoretical framework regarding the
parameters from which treatment satisfaction is being
compared in this study, it is important to consider that:
a) participants were not receiving any treatment for at
least six months before randomization; b) most partici-
pants enrolled into this treatment hoping to receive
injectable medications; c) the ‘methadone’ group never
received injectable medications, however the injectable
group (as well as the oral group) did in the past receive
oral methadone (the gold standard to compare with);
and d) the unidimensional factor structure of the CSQ-8
may have yielded an overestimation of satisfaction. A
‘social desirability bias’ (reply in a manner that will be
viewed favourably by others) may also have influenced
some participants’ responses, accounting for the positive
responses.
Conclusions
Among long-term chronic opioid injectors participating
in a randomized clinical trial prescribing injectable dia-
cetylmorphine or hydromorphone and oral methadone,
those receiving injectable medications were more satis-
fied with treatment. Independent of treatment group,
treatment satisfaction was also an indicator of retention
in treatment, as well as treatment response, including a
reduction in substance use. As the first study in North
America to provide injectable OST, these findings have
valuable implications for future RCTs, which should
continue to measure satisfaction in order to identify
areas of improvement. These findings also provide evi-
dence-based knowledge for good clinical practice guide-
lines in the treatment of chronic opioid dependence in
Canada as they highlight the association between treat-
ment satisfaction and improved treatment outcomes,
particularly for those receiving more innovative treat-
ment medications.
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